vs
SOLAI Ltd（SLAI）与Xilio Therapeutics, Inc.（XLO）财务数据对比。点击上方公司名可切换其他公司
Xilio Therapeutics, Inc.的季度营收约是SOLAI Ltd的1.2倍（$13.7M vs $11.0M），Xilio Therapeutics, Inc.净利率更高（75.7% vs -126.2%，领先201.9%），Xilio Therapeutics, Inc.自由现金流更多（$-2.1M vs $-17.0M）
Xilio Therapeutics是一家临床阶段生物技术企业，专注开发用于多种癌症治疗的新型肿瘤选择性免疫疗法，其在研候选药物可在肿瘤微环境中特异性激活抗肿瘤免疫反应，降低全身性毒副作用，主要面向北美及全球其他地区的肿瘤患者群体。
SLAI vs XLO — 直观对比
营收规模更大
XLO
是对方的1.2倍
$11.0M
净利率更高
XLO
高出201.9%
-126.2%
自由现金流更多
XLO
多$14.9M
$-17.0M
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $11.0M | $13.7M |
| 净利润 | $-13.9M | $10.4M |
| 毛利率 | 0.1% | — |
| 营业利润率 | -126.2% | -86.5% |
| 净利率 | -126.2% | 75.7% |
| 营收同比 | -43.1% | — |
| 净利润同比 | -173.4% | 179.1% |
| 每股收益（稀释后） | $-0.01 | $-3.74 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收SLAIXLO
| Q4 25 | — | $13.7M | ||
| Q3 25 | — | $19.1M | ||
| Q2 25 | $11.0M | $8.1M | ||
| Q1 25 | — | $2.9M | ||
| Q2 24 | $19.4M | — |
净利润SLAIXLO
| Q4 25 | — | $10.4M | ||
| Q3 25 | — | $-16.3M | ||
| Q2 25 | $-13.9M | $-15.8M | ||
| Q1 25 | — | $-13.3M | ||
| Q2 24 | $18.9M | — |
毛利率SLAIXLO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | — | — | ||
| Q2 24 | 52.4% | — |
营业利润率SLAIXLO
| Q4 25 | — | -86.5% | ||
| Q3 25 | — | -10.1% | ||
| Q2 25 | -126.2% | -177.7% | ||
| Q1 25 | — | -472.7% | ||
| Q2 24 | -2.6% | — |
净利率SLAIXLO
| Q4 25 | — | 75.7% | ||
| Q3 25 | — | -85.4% | ||
| Q2 25 | -126.2% | -196.0% | ||
| Q1 25 | — | -452.7% | ||
| Q2 24 | 97.9% | — |
每股收益（稀释后）SLAIXLO
| Q4 25 | — | $-3.74 | ||
| Q3 25 | — | $-0.11 | ||
| Q2 25 | $-0.01 | $-0.16 | ||
| Q1 25 | — | $-0.18 | ||
| Q2 24 | $0.02 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.2M | $137.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $43.8M | $35.3M |
| 总资产 | $69.1M | $154.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资SLAIXLO
| Q4 25 | — | $137.5M | ||
| Q3 25 | — | $103.8M | ||
| Q2 25 | $1.2M | $121.6M | ||
| Q1 25 | — | $89.1M | ||
| Q2 24 | $2.3M | — |
股东权益SLAIXLO
| Q4 25 | — | $35.3M | ||
| Q3 25 | — | $-8.1M | ||
| Q2 25 | $43.8M | $7.1M | ||
| Q1 25 | — | $10.7M | ||
| Q2 24 | $45.9M | — |
总资产SLAIXLO
| Q4 25 | — | $154.7M | ||
| Q3 25 | — | $133.7M | ||
| Q2 25 | $69.1M | $133.8M | ||
| Q1 25 | — | $103.7M | ||
| Q2 24 | $63.3M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-17.0M | $-2.0M |
| 自由现金流经营现金流 - 资本支出 | $-17.0M | $-2.1M |
| 自由现金流率自由现金流/营收 | -154.2% | -15.3% |
| 资本支出强度资本支出/营收 | 0.0% | 0.7% |
| 现金转化率经营现金流/净利润 | — | -0.19× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流SLAIXLO
| Q4 25 | — | $-2.0M | ||
| Q3 25 | — | $-17.5M | ||
| Q2 25 | $-17.0M | $-14.5M | ||
| Q1 25 | — | $29.0M | ||
| Q2 24 | $-12.1M | — |
自由现金流SLAIXLO
| Q4 25 | — | $-2.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | $-17.0M | $-14.9M | ||
| Q1 25 | — | $29.0M | ||
| Q2 24 | — | — |
自由现金流率SLAIXLO
| Q4 25 | — | -15.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | -154.2% | -184.0% | ||
| Q1 25 | — | 988.3% | ||
| Q2 24 | — | — |
资本支出强度SLAIXLO
| Q4 25 | — | 0.7% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | 0.0% | 5.0% | ||
| Q1 25 | — | 0.8% | ||
| Q2 24 | — | — |
现金转化率SLAIXLO
| Q4 25 | — | -0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q2 24 | -0.64× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
SLAI
| Data center | $6.5M | 59% |
| Cryptocurrency mining | $4.6M | 41% |
XLO
暂无分部数据
